Vascular Calcification Markers and Hemodialysis Vascular Access Complications

Background: Arteriovenous (AV) access dysfunction is a common complication in hemodialysis patients. Markers of vascular calcification are associated with cardiovascular outcomes and mortality in this population, but their association with vascular access outcomes is unknown. In this study, we aimed to evaluate the association between selected vascular calcification makers and vascular access complications in a cohort of hemodialysis patients. Method: Fetuin-A, osteopontin (OPN), osteoprotegerin (OPG), and bone morphogenetic protein-7 (BMP-7) were measured in blood samples from 219 dialysis patients in the Choice for Healthy Outcomes in Caring for end-stage renal disease study; these patients were using a permanent vascular access. Participants were followed for up to 1 year or until the occurrence of a vascular access intervention or replacement. Associations with AV fistula (AVF) and AV graft (AVG) intervention-free survival were assessed in models adjusted for demographic characteristics, comorbidities, and inflammation. Results: A total of 24 out 103 participants with an AVF and 43 out of 116 participants with an AVG had an intervention during follow-up. Lower fetuin-A, higher OPN, and higher BMP-7 were associated with a higher risk of AVF intervention (adjusted hazard ratios [aHR] for highest versus lowest tertile = 0.30 [95% CI 0.10–0.94]) for fetuin-A, 3.84 (95% CI 1.16–12.74) for OPN, and 3.49 (95% CI 1.16–10.52) for BMP-7. OPG was not significantly associated with the risk of AVF intervention. The associations of OPN and BMP-7 with AVF intervention appeared stronger among participants without diabetes (aHR 8.06; 95% CI 1.11–58.57 for OPN and aHR 2.55; 95% CI 1.08–6.08 for BMP-7, respectively) than among their counterparts with diabetes (p interaction = 0.06). None of the markers studied were significantly associated with AVG interventions. Conclusion: Lower fetuin-A and higher OPN and BMP-7 are associated with complications in AVF but not in AVG, suggesting a role for calcification in the pathogenesis AVF failure.

[1]  M. Allon,et al.  New Insights into Dialysis Vascular Access: Impact of Preexisting Arterial and Venous Pathology on AVF and AVG Outcomes. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[2]  Chul-woo Yang,et al.  Pre‐existing Arterial Micro‐Calcification Predicts Primary Unassisted Arteriovenous Fistula Failure in Incident Hemodialysis Patients , 2015, Seminars in dialysis.

[3]  J. Floege,et al.  Impact of Vascular Calcifications on Arteriovenous Fistula Survival in Hemodialysis Patients: A Five-Year Follow-Up , 2015, Nephron.

[4]  Timmy Lee.  Vascular Access Calcification and Arteriovenous Fistula Maturation , 2014 .

[5]  N. Powe,et al.  Biomarkers of vascular calcification and mortality in patients with ESRD. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[6]  C. Jenkinson,et al.  The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus , 2014, Acta Diabetologica.

[7]  Timmy Lee.  Novel paradigms for dialysis vascular access: downstream vascular biology--is there a final common pathway? , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[8]  D. Oh,et al.  Serum osteoprotegerin level is associated with degree of arteriovenous fistula stenosis in patients with hemodialysis. , 2013, Clinical nephrology.

[9]  S. Douma,et al.  Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients , 2013, BMC Nephrology.

[10]  P. Quax,et al.  Arteriovenous access failure: more than just intimal hyperplasia? , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  F. Dekker,et al.  Type of arteriovenous vascular access and association with patency and mortality , 2013, BMC Nephrology.

[12]  V. Garg,et al.  Role of fetuin‐A in atherosclerosis associated with diabetic patients , 2012, The Journal of pharmacy and pharmacology.

[13]  M. Budoff,et al.  Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[14]  E. Coche,et al.  Serum fetuin-A levels are associated with vascular calcifications and predict cardiovascular events in renal transplant recipients. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[15]  S. Nicholas,et al.  Activation of Vascular Bone Morphogenetic Protein Signaling in Diabetes Mellitus , 2011, Circulation research.

[16]  K. Wu,et al.  Association of low serum fetuin A levels with poor arteriovenous access patency in patients undergoing maintenance hemodialysis. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  S. Sasaki,et al.  Assessment and significance of abdominal aortic calcification in chronic kidney disease. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  L. Gesualdo,et al.  Serum fetuin a in hemodialysis: a link between derangement of calcium-phosphorus homeostasis and progression of atherosclerosis? , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  F. Dekker,et al.  Vascular access calcification predicts mortality in hemodialysis patients. , 2008, Kidney international.

[20]  L. Hofbauer,et al.  The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  M. Bots,et al.  Hemodialysis arteriovenous fistula patency revisited: results of a prospective, multicenter initiative. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[22]  L. Hofbauer,et al.  Exploring the biology of vascular calcification in chronic kidney disease: what's circulating? , 2008, Kidney international.

[23]  Prabir Roy-Chaudhury,et al.  Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. , 2006, Journal of the American Society of Nephrology : JASN.

[24]  Josef Coresh,et al.  Comparing the Risk for Death with Peritoneal Dialysis and Hemodialysis in a National Cohort of Patients with Chronic Kidney Disease , 2005, Annals of Internal Medicine.

[25]  K. Hruska,et al.  Bone Morphogenetic Proteins in Vascular Calcification , 2005, Circulation research.

[26]  N. Chen,et al.  Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). , 2005, Kidney international.

[27]  V. Jorgetti,et al.  Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. , 2005, Kidney international.

[28]  N. Chen,et al.  Pathophysiology of Vascular Calcification in Chronic Kidney Disease , 2004, Circulation research.

[29]  L. Hofbauer,et al.  Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. , 2004, JAMA.

[30]  N. Powe,et al.  Changes in quality of life during hemodialysis and peritoneal dialysis treatment: generic and disease specific measures. , 2004, Journal of the American Society of Nephrology : JASN.

[31]  N. Powe,et al.  Patient ratings of dialysis care with peritoneal dialysis vs hemodialysis. , 2004, JAMA.

[32]  G. London,et al.  Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  A. Schwarz,et al.  The serum protein α2–Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification , 2003 .

[34]  C. Wanner,et al.  Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study , 2003, The Lancet.

[35]  Nancy Fink,et al.  The Timing of Specialist Evaluation in Chronic Kidney Disease and Mortality , 2002, Annals of Internal Medicine.

[36]  E W Young,et al.  Type of vascular access and mortality in U.S. hemodialysis patients. , 2001, Kidney international.

[37]  C. Giachelli,et al.  Osteopontin: a versatile regulator of inflammation and biomineralization. , 2000, Matrix biology : journal of the International Society for Matrix Biology.

[38]  C. Giachelli,et al.  Phosphorylation of Osteopontin Is Required for Inhibition of Vascular Smooth Muscle Cell Calcification* , 2000, The Journal of Biological Chemistry.

[39]  D. Laskin,et al.  Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macrophages , 1996, Journal of leukocyte biology.

[40]  H. Feldman,et al.  Hemodialysis vascular access morbidity. , 1996, Journal of the American Society of Nephrology : JASN.

[41]  D. Laskin,et al.  Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. , 1994, The Journal of biological chemistry.

[42]  C. Alpers,et al.  Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. , 1993, The Journal of clinical investigation.

[43]  C. Reutelingsperger,et al.  Vascular calcification in chronic kidney disease: an update. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[44]  E. Cavalier,et al.  Vascular calcification: from pathophysiology to biomarkers. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[45]  N. Chen,et al.  Vascular calcification in chronic kidney disease. , 2004, Seminars in nephrology.

[46]  W. Jahnen-Dechent,et al.  Systemic inhibition of spontaneous calcification by the serum protein alpha 2-HS glycoprotein/fetuin. , 2001, Zeitschrift fur Kardiologie.

[47]  W. Jahnen-Dechent,et al.  Systemic inhibition of spontaneous calcification by the serum protein α2-HS glycoprotein/fetuin , 2001, Zeitschrift für Kardiologie.

[48]  N. Saunders,et al.  Modification of macrophage response to lipopolysaccharide by fetuin. , 1998, Immunology letters.